CRP and Sacroiliac arthritis: Indeed, pooled post hoc analyses of PsA patients (pts) with investigator-confirmed sacroiliitis (prior imaging or radiograph at screening) showed that GUS-treated pts had significantly greater improvements in axial-related symptoms (evaluated by BASDAI, modified BASDAI, and ASDAS-CRP) vs. placebo at week (W) 24, with improvements maintained through W52.